First of all, instead of the measured docetaxel response in prostate cancer patients, we utilized the docetaxel sensitivity score imputed using patients’ RNAseq data to perform the correlation between GAS5 expression and docetaxel response. This evidence concerns the gene GAS5 and prostate carcinoma.